Skip to main content
. 2018 Apr 27;9(5):469. doi: 10.1038/s41419-018-0482-4

Fig. 3. FoxM1 transcriptionally promotes ADAM17 expression through binding to the promoter of ADAM17.

Fig. 3

a, b qRT-PCR and western blot were performed to investigated the effects of altering the expression of FoxM1 on that of ADAM17 in glioma cells. The data are means ± SD from three independent experiments. Student’s t test was used to determine the significance of the differences between the groups (#P < 0.0001, Student’s t test). c The sites and mutant sites of FoxM1 binding to ADAM17 promoter. d FoxM1 overexpression increased the ADAM17 promotor activity. The data are shown as the mean ± s.d. of three independent experiments. Student’s t test was used to determine the significance of the differences between the groups (**P < 0.01, Student’s t test). e The luciferase report assay was used to determine the importance of the binding sites on ADAM17 promoter activity. The data are shown as the mean ± s.d. of three independent experiments. Student’s t test was used to determine the significance of the differences between the groups (*P < 0.05, **P < 0.01, ***P < 0.001, #P < 0.0001, Student’s t test). f Results of ChIP assay performed with glioma cells to detect the binding between FoxM1 and ADAM17 promoter